News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CF PHARMTECH (02652.HK) Class I New Drug ICF004 Clinical Trial Application Approved in China
CF PHARMTECH (02652.HK) announced that the Investigational New Drug (IND) application for its Class I new drug ICF004 inhalation powder has recently been approved by the National M...
Reset
Send
The window will close in 5 seconds
CF PHARMTECH (02652.HK) Class I New Drug ICF004 Clinical Trial Application Approved in China
Close
Recommend
2
Positive
1
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CF PHARMTECH (02652.HK)  -0.710 (-3.827%)    Short selling $184.90K; Ratio 1.042%   announced that the Investigational New Drug (IND) application for its Class I new drug ICF004 inhalation powder has recently been approved by the National Medical Products Administration (NMPA) of China.

The product is intended for the treatment of interstitial lung disease (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-11 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.